# US 8,278,042 B2 · Compositions and methods for the diagnosis and treatment of tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,042 B2
- Document ID: US8278042B2
- Status: Granted
- Kind: B2
- Application number: 12/661,704
- Filed: 2010-03-22
- Published: 2010-12-09
- Granted: 2012-10-02
- Earliest claimed: 2001-06-20
- Assignees: Genentech, Inc.
- Inventors: Belinda Cairns; Ruihuan Chen; Gretchen Frantz; Kenneth J. Hillan; Hartmut Koeppen; Heidi S. Phillips; Paul Polakis; Susan D. Spencer; Victoria Smith; P. Mickey Williams; Thomas D. Wu; Zemin Zhang
- Web page: https://patentgrep.com/patent/US8278042B2

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- C07K 16/3023: {Lung}
- C07K 16/40: against enzymes
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

## Claims

### Claim 1

A method of diagnosing the presence of a cancerous lung tumor in a human subject, said method comprising determining the level of the nucleotide sequence of SEQ ID NO: 29, in a test sample of lung tissue cells taken from said human subject suspected of containing cancerous lung tumor cells and in a control sample of known normal cells taken from human lung, wherein a higher level of said nucleotide sequence of SEQ ID NO: 29 in the test sample, as compared to the control sample, is diagnostic of the presence of a cancerous lung tumor in the human subject from which the test sample was obtained.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of determining the level of said nucleotide sequence of SEQ ID NO: 29 comprises employing an oligonucleotide in an in situ hybridization or reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said nucleotide sequence of SEQ ID NO: 29 encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:107.
